VR
VRTX34.SA Vertex Pharmaceuticals Incorporated
- Market cap
- BRL 758B
- P/E
- 36.9x
- P/B
- 6.74x
- ROE
- 17.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is VRTX34.SA undervalued?
Graham numberThe Graham number of Vertex Pharmaceuticals Incorporated cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vertex Pharmaceuticals Incorporated fundamental analysis
No fundamental analysis for Vertex Pharmaceuticals Incorporated yet.
Vertex Pharmaceuticals Incorporated stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for …
Full company profileVertex Pharmaceuticals Incorporated financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vertex Pharmaceuticals Incorporated annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.70B | 2.49B | 3.05B | 4.16B | 6.21B | 7.57B | 8.93B | 9.87B | 11.0B | 12.0B | 13.0B |
| Gross Profit | 1.49B | 2.21B | 2.64B | 3.62B | 5.47B | 6.67B | 7.85B | 8.61B | 9.49B | 10.4B | 11.1B |
| Operating Income | 11.2M | 393M | 664M | 1.20B | 2.87B | 2.78B | 4.31B | 3.83B | -233M | 4.17B | 4.21B |
| EBITDA | - | 103M | 707M | 1.56B | 3.28B | 2.79B | 4.29B | 4.61B | 486M | 4.87B | 4.54B |
| Net Income | -112M | 263M | 2.10B | 1.18B | 2.71B | 2.34B | 3.32B | 3.62B | -536M | 3.95B | 3.71B |
| EPS | - | 1.04 | 8.22 | 4.54 | 10 | 9.20 | 13 | 14 | -2.08 | 16 | 15 |
| Balance Sheet | |||||||||||
| Total Assets | 2.90B | 3.55B | 6.25B | 8.32B | 11.8B | 13.4B | 18.2B | 22.7B | 22.5B | 25.6B | 32.7B |
| Total Liabilities | 1.56B | 1.50B | 1.81B | 2.23B | 3.06B | 3.33B | 4.24B | 5.15B | 6.12B | 6.98B | 11.8B |
| Shareholders' Equity | 1.16B | 2.03B | 4.44B | 6.09B | 8.69B | 10.1B | 13.9B | 17.6B | 16.4B | 18.7B | 20.9B |
| Cash & Short-term Investments | 1.43B | 2.09B | 3.17B | 3.81B | 6.66B | 7.52B | 10.8B | 11.2B | 6.12B | 6.61B | 4.98B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 236M | 845M | 1.27B | 1.57B | 3.25B | 2.64B | 4.13B | 4.38B | -493M | 3.63B | 4.26B |
| Capital Expenditure | 56.6M | 99.4M | 95.4M | 75.4M | 260M | 235M | 205M | 176M | 485M | 438M | 457M |
| Free Cash Flow | - | 586M | 1.17B | 1.49B | 2.99B | 2.41B | 3.93B | 4.21B | -978M | 3.19B | 3.80B |
| Ratios | |||||||||||
| ROE | -9.7% | 13.0% | 47.3% | 19.3% | 31.2% | 23.2% | 23.9% | 20.6% | -3.3% | 21.2% | 17.8% |
| ROA | -3.9% | 7.4% | 33.6% | 14.1% | 23.1% | 17.4% | 18.3% | 15.9% | -2.4% | 15.4% | 11.3% |
| Net Profit Margin | -6.6% | 10.6% | 68.8% | 28.3% | 43.7% | 30.9% | 37.2% | 36.7% | -4.9% | 32.9% | 28.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Vertex Pharmaceuticals Incorporated dividends
Vertex Pharmaceuticals Incorporated has not paid dividends in the last 9 fiscal years.
Last stock split: 8:1 on Jul 27, 2026.
Who owns Vertex Pharmaceuticals Incorporated
- Insiders 0.00%
- Institutions 0.04%
- Public & others 99.96%
- Shares outstanding 8.11B
- Free float 8.15B
Vertex Pharmaceuticals Incorporated company profile
- Company name
- Vertex Pharmaceuticals Incorporated
- Ticker
- VRTX34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6,400
- Fiscal year end
- December
- Address
- 50 Northern Avenue, Boston, MA, United States, 02210
- Phone
- 617 341 6100
- Website
- vrtx.com
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Vertex Pharmaceuticals Incorporated management
10- Dr. Jeffrey Marc Leiden M.D., Ph.D.Executive Chairman · born 1956
- Dr. Reshma Kewalramani FASN, M.D.CEO, President & Director · born 1973
- Mr. Charles F. Wagner Jr.Executive VP, COO & CFO · born 1968
- Mr. Amit K. Sachdev J.D.Executive VP & Chief Patient and External Affairs Officer · born 1968
- Dr. Ourania Tatsis Ph.D.Executive VP & Chief Product Affairs Officer · born 1970
- Dr. Carmen Bozic M.D.Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer · born 1963
- Ms. Kristen C. Ambrose CPASenior VP & Chief Accounting Officer · born 1976
- Dr. Mark Bunnage D.PhilExecutive VP & Chief Scientific Officer · born 1969
- Ms. Susie Lisa C.F.A.Senior Vice President of Investor Relations
- Ms. Joy Liu J.D.EVP, Chief Legal Officer & Corporate Secretary · born 1978